NCT00651534已完成1 期
An Open-label, Randomized, Five Period Crossover Study to Estimate the Relative Bioavailability of Five Formulations of 400 mg Ronacaleret (a Calcium-sensing Receptor Antagonist) Administered as a Single Oral Dose to Healthy Postmenopausal Females.
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 32
- 试验地点
- 2
研究概览
简要总结
This study will examine the effects of formulation on the relative bioavailability of SB-751689 (400 mg) administered to healthy postmenopausal women. Subjects will receive a single oral dose of each formulation, with five formulations of SB-751689 tested in total. Blood samples will be taken up to 24 hours postdose after each dose administration. This study will provide information for future possible formulation development of SB-751689 for Phase III.
研究设计
- 研究类型
- Interventional
入排标准
- 性别
- Female
- 接受健康志愿者
- 是
入选标准
- •Healthy postmenopausal women
- •Non-smokers
- •Body weight > or = 50 kg and BMI within the range 19-32 kg/m2
- •Capable of giving written informed consent and complying with the requirements and restrictions listed in the consent form
- •QTcB or QTcF < 450 msec; or QTc < 480 msec in subjects with Bundle Branch Block
- •Hispanic or non-Hispanic (Caucasian) ethnicity
排除标准
- •Any clinically relevant biological or physical abnormality found or reported at screening which, in the opinion of the investigator, is clinically significant and would preclude safe participation in this study
- •Positive urine drug screen at screening
- •Positive urine test for alcohol at pre-dose
- •Positive for HIV or hepatitis B or C virus at screening
- •Urinary cotinine levels indicative of smoking at screening
- •History of smoking or use of nicotine containing products within one year of the study or >10 pack-year history of smoking overall
- •History of regular alcohol consumption exceeding 7 units/week (1 unit = 5 ounces of wine or 12 ounces of beer or 1.5 ounces of hard liquor) within 6 months of screening
- •History of drug abuse within 6 months of the study
- •Participation in a clinical study and received a drug or a new chemical entity with 30 days or 5 half-lives, or twice the duration of the biological effect of any drug (whichever is longer) prior to the first dose of the current study medication.
- •Exposure to more than four new chemical entities within 12 months prior to the first dosing day.
- •Use of prescription or non-prescription drugs
- •Consumption of red wine, grapefruit, grapefruit juice or grapefruit containing products within 14 days prior to the first dose of study medication
- •Donation of blood in excess of 500 mL within 56 days prior to dosing
- •Evidence of renal, hepatic or biliary impairment
- •History of serious gastrointestinal disease
- •History of sensitivity to any of the study medications or components thereof or a history of drug or other allergy that, in the opinion of the physician responsible, contraindicates their participation.
- •History of clinically significant cardiovascular disease
- •Medical conditions that might alter bone metabolism
- •Serum parathyroid hormone (iPTH) test levels outside the reference range at screening
- •Liver function tests, parathyroid hormone test or CPK outside the reference range at screening
研究者
研究点 (2)
Loading locations...
相似试验
已完成
1 期
A Study to Estimate the Effect of Formulation on the Relative Absorption of SB-751689 Administered to Healthy WomenOsteoporosisNCT00540878GlaxoSmithKline25
已完成
1 期
A Relative Bioavailability Study of SSP-004184AQ (Magnesium Salt) and SSP-004184SS (Disodium Salt)HealthyNCT01905540Shire28
已完成
1 期
Evaluation Of The Relative Bioavailability Of PF-04457845 Tablet To Solution Formulation And Food Effect In Healthy SubjectsHealthy VolunteersNCT00918164Pfizer12
已完成
1 期
Relative Bioavailability of BI 207127 Trial Formulation II Prototypes Versus BI 207127 Trial Formulation I in Healthy VolunteersHealthyNCT02182414Boehringer Ingelheim42
尚未招募
1 期
A Relative Bioavailability and Food Effect Study of HDM1002 in Healthy SubjectsHealthy Adult SubjectNCT06608329Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.33